Alzheimer’s disease (AD) disproportionately affects females with steeper cognitive decline and more neuropathology compared to males, which is exacerbated in females carrying the APOEɛ4 allele. The risk of developing AD is also higher in female APOEɛ4 carriers in earlier age groups (aged 65–75), and the progression from cognitively normal to mild cognitive impairment (MCI) and to AD may be influenced by sex. Inflammation is observed in AD and is related to aging, stress, and neuroplasticity, and although studies are scarce, sex differences are noted in inflammation.
Objective:
The objective of this study was to investigate underlying physiological inflammatory mechanisms that may help explain why there are sex differences in AD and APOEɛ4 carriers.
Methods:
We investigated, using the ADNI database, the effect of sex and APOE genotype (non-carriers or carriers of 1 and 2 APOEɛ4 alleles) and sex and diagnosis (cognitively normal (CN), MCI, AD) on CSF (N = 279) and plasma (N = 527) markers of stress and inflammation.
Results:
We found CSF IL-16 and IL-8 levels differed by sex and APOE genotype, as IL-16 was higher in female APOEɛ4 carriers compared to non-carriers, while the opposite pattern was observed in males with IL-8. Furthermore, females had on average higher levels of plasma CRP and ICAM1 but lower levels of CSF ICAM1, IL-8, IL-16, and IgA than males. Carrying APOEɛ4 alleles and diagnosis (MCI and AD) decreased plasma CRP in both sexes.
Conclusion:
Sex and APOE genotype differences in CSF and plasma inflammatory biomarkers support that the underlying physiological changes during aging differ by sex and tissue origin.
Alzheimer’s Association (2017) 2017 Alzheimer’s disease facts and figures. Alzheimers Dement13, 325–373.
2.
CarusoA, NicolettiF, MangoD, SaidiA, OrlandoR, ScaccianoceS (2018) Stress as risk factor for Alzheimer’s disease. Pharmacol Res132, 130–134.
3.
BaumgartM, SnyderHM, CarrilloMC, FazioS, KimH, JohnsH (2015) Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimers Dement11, 718–726.
4.
NebelRA, AggarwalNT, BarnesLL, GallagherA, GoldsteinJM, KantarciK, MallampalliMP, MorminoEC, ScottL, YuWH, MakiPM, MielkeMM (2018) Understanding the impact of sex and gender in Alzheimer’s disease: A call to action. Alzheimers Dement14, 1171–1183.
RiedelBC, ThompsonPM, BrintonRD (2016) Age, APOE and sex: Triad of risk of Alzheimer’s disease. J Steroid Biochem Mol Biol160, 134–147.
7.
LawsKR, IrvineK, GaleTM (2018) Sex differences in Alzheimer’s disease. Curr Opin Psychiatr31, 133–139.
8.
MielkeMM (2018) Sex and gender differences in Alzheimer’s disease dementia. Psychiatr Times35, 14–17.
9.
IrvineK, LawsKR, GaleTM, KondelTK (2012) Greater cognitive deterioration in women than men with Alzheimer’s disease: A meta analysis. J Clin Exp Neuropsychol34, 989–998.
10.
LinKA, ChoudhuryKR, RathakrishnanBG, MarksDM, PetrellaJR, DoraiswamyPM (2015) Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement1, 103–110.
11.
WangX, ZhouW, YeT, LinX, ZhangJ, Alzheimer’s Disease Neuroimaging Initiative (2019) Sex difference in the association of APOE4 with memory decline in mild cognitive impairment. J Alzheimers Dis69, 1161–1169.
12.
ArdekaniBA, ConvitA, BachmanAH (2016) Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. J Alzheimers Dis50, 847–857.
13.
BarnesLL, WilsonRS, BieniasJL, SchneiderJA, EvansDA, BennettDA (2005) Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry62, 685–691.
14.
HollandD, DesikanRS, DaleAM, McEvoyLK, Alzheimer’s Disease Neuroimaging Initiative (2013) Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol34, 2287–2293.
15.
HuaX, HibarDP, LeeS, TogaAW, JackCR, WeinerMW, ThompsonPM (2010) Sex and age differences in atrophic rates: An ADNI study with=1368 MRI scans. Neurobiol Aging31, 1463–1480.
16.
NeuSC, PaJ, KukullW, BeeklyD, KuzmaA, GangadharanP, WangL.-S, RomeroK, ArnericSP, RedolfiA, OrlandiD, FrisoniGB, AuR, DevineS, AuerbachS, EspinosaA, BoadaM, RuizA, JohnsonSC, KoscikR, WangJ.-J, HsuW.-C, ChenY.-L, TogaAW (2017) Apolipoprotein E genotype and sex risk factors for Alzheimer disease: A meta-analysis. JAMA Neurol74, 1178–1189.
17.
BeydounMA, BoueizA, AbougergiMS, Kitner-TrioloMH, BeydounHA, ResnickSM, O’BrienR, ZondermanAB (2012) Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging33, 720–731.e4.
18.
HohmanTJ, DumitrescuL, BarnesLL, ThambisettyM, BeechamG, KunkleB, GiffordKA, BushWS, ChibnikLB, MukherjeeS, JagerPLD, KukullW, CranePK, ResnickSM, KeeneCD, MontineTJ, SchellenbergGD, HainesJL, ZetterbergH, BlennowK, LarsonEB, JohnsonSC, AlbertM, BennettDA, SchneiderJA, JeffersonAL (2018) Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol75, 989–998.
19.
KoranMEI, WagenerM, HohmanTJ, Alzheimer’s Neuroimaging Initiative (2017) Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav11, 205–213.
20.
HeppnerFL, RansohoffRM, BecherB (2015) Immune attack: The role of inflammation in Alzheimer disease. Nat Rev Neurosci16, 358–372.
21.
KinneyJW, BemillerSM, MurtishawAS, LeisgangAM, SalazarAM, LambBT (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement4, 575–590.
22.
SwardfagerW, LanctôtK, RothenburgL, WongA, CappellJ, HerrmannN (2010) A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry68, 930–941.
23.
EnglerH, BensonS, WegnerA, SpreitzerI, SchedlowskiM, ElsenbruchS (2016) Men and women differ in inflammatory and neuroendocrine responses to endotoxin but not in the severity of sickness symptoms. Brain Behav Immun52, 18–26.
24.
KleinSL, FlanaganKL (2016) Sex differences in immune responses. Nat Rev Immunol16, 626–638.
25.
WegnerA, BensonS, RebernikL, SpreitzerI, JägerM, SchedlowskiM, ElsenbruchS, EnglerH (2017) Sex differences in the pro-inflammatory cytokine response to endotoxin unfold in vivo but not ex vivo in healthy humans. Innate Immun23, 432–439.
26.
MárquezEJ, ChungC, MarchesR, RossiRJ, Nehar-BelaidD, ErogluA, MellertDJ, KuchelGA, BanchereauJ, UcarD (2020) Sexual-dimorphism in human immune system aging. Nat Commun11, 751.
27.
WalkerKA, WindhamBG, BrownIV CH, KnopmanDS, JackCRJr, MosleyTHJr, SelvinE, WongDF, HughesTM, ZhouY, GrossAL, GottesmanRF (2018) The association of mid- and late-life systemic inflammation with brain amyloid deposition: The ARIC-PET Study. J Alzheimers Dis66, 1041–1052.
28.
WalkerKA, GottesmanRF, WuA, KnopmanDS, GrossAL, MosleyTH, SelvinE, WindhamBG (2019) Systemic inflammation during midlife and cognitive change over 20 years. Neurology92, e1256–e1267.
29.
DantzerR (2018) Neuroimmune interactions: From the brain to the immune system and vice versa. Physiol Rev98, 477–504.
30.
de MirandaAS, ZhangC.-J, KatsumotoA, TeixeiraAL (2017) Hippocampal adult neurogenesis: Does the immune system matter?J Neurol Sci372, 482–495.
31.
ApostolovaLG, DuttonRA, DinovID, HayashiKM, TogaAW, CummingsJL, ThompsonPM (2006) Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol63, 693–699.
32.
PetersenRC, JackCR, XuYC, WaringSC, O’BrienPC, SmithGE, IvnikRJ, TangalosEG, BoeveBF, KokmenE (2000) Memory and MRI-based hippocampal volumes in aging and AD. Neurology54, 581–587.
33.
DoeckeJD, LawsSM, FauxNG, WilsonW, BurnhamSC, LamC.-P, MondalA, BedoJ, BushAI, BrownB, RuyckKD, EllisKA, FowlerC, GuptaVB, HeadR, MacaulaySL, PertileK, RoweCC, RembachA, RodriguesM, RumbleR, SzoekeC, TaddeiK, TaddeiT, TrounsonB, AmesD, MastersCL, MartinsRN, Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol69, 1318–1325.
LupienSJ, de LeonM, de SantiS, ConvitA, TarshishC, NairNP, ThakurM, McEwenBS, HaugerRL, MeaneyMJ (1998) Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci1, 69–73.
36.
MurphyKJ, HodgesTE, SheppardPAS, TroyerAK, HampsonE, GaleaLAM (2020) Sex differences in cortisol and memory following acute social stress in amnestic mild cognitive impairment. J Clin Exp Neuropsychol. https://doi.org/10.1080/13803395.2020.1825633
37.
McEwenBS, BironCA, BrunsonKW, BullochK, ChambersWH, DhabharFS, GoldfarbRH, KitsonRP, MillerAH, SpencerRL, WeissJM (1997) The role of adrenocorticoids as modulators of immune function in health and disease: Neural, endocrine and immune interactions. Brain Res Rev23, 79–133.
BenjaminiY, HochbergY (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series Stat Methodol B57, 289–300.
43.
ZouGY (2007) Toward using confidence intervals to compare correlations. Psychol Methods12, 399–413.
44.
R Core Team (2018) R: A language and environment for statistical computingR Foundation for Statistical Computing, Vienna, Austria., R Foundation for Statistical Computing, Vienna, Austria.
45.
BettcherBM, JohnsonSC, FitchR, CasalettoKB, HeffernanKS, AsthanaS, ZetterbergH, BlennowK, CarlssonCM, NeuhausJ, BendlinBB, KramerJH (2018) CSF and plasma levels of inflammation differentially relate to CNS markers of Alzheimer’s disease pathology and neuronal damage. J Alzheimers Dis62, 385–397.
46.
SetiawanE, WilsonAA, MizrahiR, RusjanPM, MilerL, RajkowskaG, SuridjanI, KennedyJL, RekkasPV, HouleS, MeyerJH (2015) Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry72, 268–275.
47.
TheendakaraV, Peters-LibeuCA, BredesenDE, RaoRV (2018) Transcriptional effects of ApoE4: Relevance to Alzheimer’s disease. Mol Neurobiol55, 5243–5254.
48.
TheendakaraV, Peters-LibeuCA, SpilmanP, PoksayKS, BredesenDE, RaoRV (2016) Direct transcriptional effects of Apolipoprotein E. J Neurosci36, 685–700.
49.
RosaMD, Dell’OmbraN, ZambitoAM, MalaguarneraM, NicolettiF, MalaguarneraL (2006) Chitotriosidase and inflammatory mediator levels in Alzheimer’s disease and cerebrovascular dementia. Eur J Neurosci23, 2648–2656.
50.
MottaM, ImbesiR, Di RosaM, StivalaF, MalaguarneraL (2007) Altered plasma cytokine levels in Alzheimer’s disease: Correlation with the disease progression. Immunol Lett114, 46–51.
51.
KoenigW, SundM, FröhlichM, FischerHG, LöwelH, DöringA, HutchinsonWL, PepysMB (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation99, 237–242.
52.
RidkerPM, BuringJE, ShihJ, MatiasM, HennekensCH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation98, 731–733.
53.
KheraA, McGuireDK, MurphySA, StanekHG, DasSR, VongpatanasinW, WiansFH, GrundySM, de LemosJA (2005) Race and gender differences in C-reactive protein levels. J Am Coll Cardiol46, 464–469.
54.
KoyamaA, O’BrienJ, WeuveJ, BlackerD, MettiAL, YaffeK (2013) The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: A meta-analysis. J Gerontol A Biol Sci Med Sci68, 433–440.
55.
EldridgeRC, WentzensenN, PfeifferRM, BrintonLA, HartgeP, GuillemetteC, KempTJ, PintoLA, TrabertB (2020) Endogenous estradiol and inflammation biomarkers: Potential interacting mechanisms of obesity-related disease. Cancer Causes Control31, 309–320.
56.
SundermannEE, PanizzonMS, ChenX, AndrewsM, GalaskoD, BanksSJ, for the Alzheimer’s Disease Neuroimaging Initiative (2020) Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone. Biol Sex Differ11, 33.
57.
HubacekJA, PeaseyA, PikhartH, StavekP, KubinovaR, MarmotM, BobakM (2010) APOE polymorphism and its effect on plasma C-reactive protein levels in a large general population sample. Hum Immunol71, 304–308.
58.
YunY.-W, KweonS.-S, ChoiJ.-S, RheeJ.-A, LeeY.-H, NamH.-S, JeongS.-K, ParkK.-S, RyuS.-Y, ChoiS.-W, KimHN, CauleyJA, ShinM.-H (2015) APOE polymorphism is associated with C-reactive protein levels but not with white blood cell count: Dong-gu Study and Namwon Study. J Korean Med Sci30, 860–865.
59.
GongC, WeiD, WangY, MaJ, YuanC, ZhangW, YuG, ZhaoY (2016) A meta-analysis of C-reactive protein in patients with Alzheimer’s Disease. Am J Alzheimers Dis Other Demen31, 194–200.
60.
NgA, TamWW, ZhangMW, HoCS, HusainSF, McIntyreRS, HoRC (2018) IL-1β, IL-6, TNF- α and CRP in elderly patients with depression or Alzheimer’s disease: Systematic review and meta-analysis. Sci Rep8, 12050.
61.
AlbaneseE, LaunerLJ, EggerM, PrinceMJ, GiannakopoulosP, WoltersFJ, EganK (2017) Body mass index in midlife and dementia: Systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. Alzheimers Dement (Amst)8, 165–178.
62.
FitzpatrickAL, KullerLH, LopezOL, DiehrP, O’MearaES, LongstrethWT, LuchsingerJA (2009) Midlife and late-life obesity and the risk of dementia: Cardiovascular Health Study. Arch Neurol66, 336–342.
63.
NguyenJCD, KillcrossAS, JenkinsTA (2014) Obesity and cognitive decline: Role of inflammation and vascular changes. Front Neurosci8, 375.
64.
ParimisettyA, DorsemansA.-C, AwadaR, RavananP, DiotelN, Lefebvre d’HellencourtC (2016) Secret talk between adipose tissue and central nervous system via secreted factors—an emerging frontier in the neurodegenerative research. J Neuroinflammation13, 67.
65.
PonthieuxA, HerbethB, DroeschS, LambertD, VisvikisS (2003) Age- and sex-related reference values for serum adhesion molecule concentrations in healthy individuals: Intercellular adhesion molecule-1 and E-, P-, and L-Selectin. Clin Chem49, 1544–1546.
66.
ZenaroE, PiacentinoG, ConstantinG (2017) The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis107, 41–56.
67.
NielsenHM, LondosE, MinthonL, JanciauskieneSM (2007) Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis26, 27–35.
68.
HuangC.-W, TsaiM.-H, ChenN.-C, ChenW.-H, LuY.-T, LuiC.-C, ChangY.-T, ChangW.-N, ChangAYW, ChangC.-C (2015) Clinical significance of circulating vascular cell adhesion molecule-1 to white matter disintegrity in Alzheimer’s dementia. Thromb Haemost114, 1230–1240.
69.
RentzosM, MichalopoulouM, NikolaouC, CambouriC, RombosA, DimitrakopoulosA, KapakiE, VassilopoulosD (2004) Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer’s disease. J Geriatr Psychiatry Neurol17, 225–231.
ChakrabartyP, TianbaiL, HerringA, Ceballos-DiazC, DasP, GoldeTE (2012) Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener7, 36.
74.
ChakrabartyP, HerringA, Ceballos-DiazC, DasP, GoldeTE (2011) Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol Neurodegener6, 16.
75.
ChakrabartyP, Ceballos-DiazC, BeccardA, JanusC, DicksonD, GoldeTE, DasP (2010) IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol184, 5333–5343.
76.
ChakrabartyP, Jansen-WestK, BeccardA, Ceballos-DiazC, LevitesY, VerbeeckC, ZubairAC, DicksonD, GoldeTE, DasP (2010) Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: Evidence against inflammation as a driving force for amyloid deposition. FASEB J24, 548–559.
77.
GhoshS, WuMD, ShaftelSS, KyrkanidesS, LaFerlaFM, OlschowkaJA, O’BanionMK (2013) Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci33, 5053–5064.
FerrettiMT, MerliniM, SpäniC, GerickeC, SchweizerN, EnzmannG, EngelhardtB, KulicL, SuterT, NitschRM (2016) T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer’s disease-like cerebral amyloidosis. Brain Behav Immun54, 211–225.
82.
FittenLJ, OrtizF, FairbanksL, BartzokisG, LuP, KleinE, CoppolaG, RingmanJ (2014) Younger age of dementia diagnosis in a Hispanic population in southern California. Int J Geriatr Psychiatry29, 586–593.
83.
MayedaER, GlymourMM, QuesenberryCP, WhitmerRA (2016) Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement12, 216–224.
84.
SteenlandK, GoldsteinFC, LeveyA, WhartonW (2016) A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African-Americans and Caucasians. J Alzheimers Dis50, 71–76.
85.
SharpES, GatzM (2011) The relationship between education and dementia: An updated systematic review. Alzheimer Dis Assoc Disord25, 289–304.
